Compare
Humacyte, Inc. vs TScan Therapeutics, Inc. vs Alector, Inc. vs X4 Pharmaceuticals, Inc
| Latest fiscal year | Humacyte, Inc. HUMA | TScan Therapeutics, Inc. TCRX | Alector, Inc. ALEC | X4 Pharmaceuticals, Inc XFOR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.04M | $10.32M | $21.05M | $35.11M |
| Revenue growth (YoY) | n/a | +266.7% | -79.1% | n/m |
| Gross margin | -376.1% (computed) | n/a | n/a | 83.6% (computed) |
| Operating margin | n/m | n/m | -741.3% | -247.4% |
| Net margin | n/m | n/m | -679.2% | -225.6% |
| Net income | -$40.83M | -$129.77M | -$142.93M | -$79.20M |
| EPS (Diluted) | -$0.26 | -$1.00 | -$1.39 | -$1.87 |
| Operating cash flow | -$105.04M | -$135.32M | -$184.03M | -$85.62M |
| Free cash flow | -$105.93M | -$139.73M | -$184.07M | -$85.62M |
| Cash & equivalents | $50.50M | $152.41M | $65.80M | $217.05M |
| Total assets | $116.37M | $228.79M | $293.24M | $290.46M |
| Total liabilities | $113.26M | $105.67M | $262.59M | $104.17M |
| Shareholders' equity | $3.11M | $123.12M | $30.65M | $186.29M |
| Return on year-end equity | n/m | -105.4% | -466.3% | -42.5% |
| Shares outstanding | 193.00M | n/a | 110.36M | 90.91M |
Revenue, most recent five fiscal years
| Fiscal year | Humacyte, Inc. | TScan Therapeutics, Inc. | Alector, Inc. | X4 Pharmaceuticals, Inc |
|---|---|---|---|---|
| Latest | $2.04M Ended 2025-12-31 | $10.32M Ended 2025-12-31 | $21.05M Ended 2025-12-31 | $35.11M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $2.82M Ended 2024-12-31 | $100.56M Ended 2024-12-31 | $2.56M Ended 2024-12-31 |
| 2 years earlier | n/a | $21.05M Ended 2023-12-31 | $97.06M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $13.54M Ended 2022-12-31 | $133.62M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $10.14M Ended 2021-12-31 | $207.09M Ended 2021-12-31 | $0 Ended 2021-12-31 |